MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611112821 A) filed by Noida Institute Of Engineering And Technology Pharmacy Institute on September 21, 2026, for Uncertainty-Aware Platform For Pharmacokinetic Profiling, Candidate Ranking, And Formulation- Guided Optimisation Of Cns Drug Candidates.
Inventors include Dr. Anjna Rani; and Pentela Bhavani.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention discloses an integrated computational platform implemented on a computing apparatus for central nervous system drug discovery comprising five interconnected modules: a multi-endpoint pharmacokinetic prediction engine employing gradient boosting models for simultaneous prediction of blood-brain barrier permeability, plasma protein binding, metabolic stability, solubility, P-glycoprotein efflux, and intestinal absorption; a conformal prediction uncertainty quantification engine providing compound-specific, distribution-free prediction intervals with guaranteed finite-sample coverage; therapeutic-area-specific classification sub-models for Alzheimer disease, Parkinson disease, epilepsy, glioblastoma, and depression with disease-specific decision boundaries; a multi-criteria decision analysis candidate ranking engine computing a composite CNS Drug Developability Index using defined desirability function parameters with uncertainty penalties; and a formulation design recommender mapping predicted biopharmaceutical profiles to dosage form strategies. The platform achieves test R-squared of 0.604 for BBB permeability, 91.5 percent empirical coverage, 82.6 percent prioritisation accuracy, and 77.1 percent formulation prediction accuracy, providing industrially applicable pharmaceutical decision support.
Disclaimer: Curated by HT Syndication.
